Legend Biotech Schedules Q4 and Full-Year 2025 Earnings Call
Event summary
- Legend Biotech will host an investor conference call on March 10, 2026, at 8:00 am ET to discuss Q4 and full-year 2025 financial results.
- The company is the largest standalone cell therapy firm with over 2,900 employees.
- Legend Biotech markets CARVYKTI®, a CAR-T cell therapy for relapsed or refractory multiple myeloma, in collaboration with Johnson & Johnson.
- A replay of the webcast and earnings press release will be available on the company's Investor Relations page post-call.
The big picture
Legend Biotech is positioning itself as a leader in the cell therapy space, particularly with its collaboration on CARVYKTI®. The upcoming earnings call will provide insights into how the company's strategic initiatives are translating into financial results and market expansion. With over 2,900 employees, Legend Biotech aims to maximize patient access and therapeutic potential, driving future innovation in cell therapy.
What we're watching
- Revenue Growth
- How Legend Biotech's financial performance will reflect the commercial success of CARVYKTI® and its expansion strategies.
- Pipeline Development
- Whether the company can sustain innovation across its pipeline of cutting-edge cell therapy modalities.
- Market Positioning
- The pace at which Legend Biotech can solidify its leadership in the CAR-T cell therapy market amid competition.
Related topics